A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer

Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have poor 5-year survival. Pharmacological ascorbate (P-AscH-, high dose, intravenous, vitamin C) has shown promise as an adjunct to chemotherapy. We hypothesized adding P-AscH- to gemcitabine and nab-paclitaxel would increase survival...

Full description

Saved in:

Bibliographic Details
Published in:	Redox biology Vol. 77; p. 103375
Main Authors:	Bodeker, Kellie L., Smith, Brian J., Berg, Daniel J., Chandrasekharan, Chandrikha, Sharif, Saima, Fei, Naomi, Vollstedt, Sandy, Brown, Heather, Chandler, Meghan, Lorack, Amanda, McMichael, Stacy, Wulfekuhle, Jared, Wagner, Brett A., Buettner, Garry R., Allen, Bryan G., Caster, Joseph M., Dion, Barbara, Kamgar, Mandana, Buatti, John M., Cullen, Joseph J.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01-11-2024 Elsevier
Subjects:	Ascorbic acid Controlled clinical trial Gemcitabine Nab-paclitaxel Pancreatic neoplasms Research Paper Ascorbic acid Gemcitabine Pancreatic neoplasms Controlled clinical trial Nab-paclitaxel
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) have poor 5-year survival. Pharmacological ascorbate (P-AscH-, high dose, intravenous, vitamin C) has shown promise as an adjunct to chemotherapy. We hypothesized adding P-AscH- to gemcitabine and nab-paclitaxel would increase survival in patients with metastatic PDAC. Patients diagnosed with stage IV pancreatic cancer randomized 1:1 to gemcitabine and nab-paclitaxel only (SOC, control) or to SOC with concomitant P-AscH−, 75 g three times weekly (ASC, investigational). The primary outcome was overall survival with secondary objectives of determining progression-free survival and adverse event incidence. Quality of life and patient reported outcomes for common oncologic symptoms were captured as an exploratory objective. Thirty-six participants were randomized; of this 34 received their assigned study treatment. All analyses were based on data frozen on December 11, 2023. Intravenous P-AscH- increased serum ascorbate levels from micromolar to millimolar levels. P-AscH- added to the gemcitabine + nab-paclitaxel (ASC) increased overall survival to 16 months compared to 8.3 months with gemcitabine + nab-paclitaxel (SOC) (HR = 0.46; 90 % CI 0.23, 0.92; p = 0.030). Median progression free survival was 6.2 (ASC) vs. 3.9 months (SOC) (HR = 0.43; 90 % CI 0.20, 0.92; p = 0.029). Adding P-AscH- did not negatively impact quality of life or increase the frequency or severity of adverse events. P-AscH− infusions of 75 g three times weekly in patients with metastatic pancreatic cancer prolongs overall and progression free survival without detriment to quality of life or added toxicity (ClinicalTrials.gov number NCT02905578). [Display omitted]
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
ISSN:	2213-2317 2213-2317
DOI:	10.1016/j.redox.2024.103375